title: [Expression of miR-130a in cisplatin resistant cell lines of ovarian cancer].
abstract: OBJECTIVE
  To determine the expression of miR-130a in cisplatin resistant cell lines of ovarian cancer and its impact on cisplatin resistance.
  
  
  METHODS
  Cisplatin resistant ovarian cancer cell lines were established by stepwise selection with gradual increase of cisplatin. MTT assay was applied to indentify the cisplatin resistant cell lines and determine their resistance index. The expression of miR-130a was measured by SYBR green real-time PCR.
  
  
  RESULTS
  The resistance index of A2780/CIS1, A2780/CIS2 and SKOV3/CIS was 30.2, 5.3 and 24.5 respectively. The SYBR green real-time PCR showed that miR-130a was over-expressed in all of the cisplatin resistant cell lines (P < 0.05). The expression of miR-130a was 30.51 times higher in A2780/CIS1, 4.87 times higher in A2780/CIS2 and 24.43 times higher in SKOV3/CIS than in their parental cell lines (P < 0.05), which was almost equally reflected in their resistance index.
  
  
  CONCLUSIONS
  The over expression of miR-130a is associated with cisplatin resistance of ovarian cancer. Inhibiting miR-130a expression may help reverse the cisplatin resistance of ovarian cancer. miR-130a is expected to be a new potential target of genetic therapy for cisplatin resistant ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu 610041, China.
authors.forename: Ling-Yun
authors.initials: LY
authors.lastname: Yang
authors.forename: Hong-Jing
authors.initials: HJ
authors.lastname: Wang
authors.forename: Xi-Biao
authors.initials: XB
authors.lastname: Jia
authors.forename: Xue
authors.initials: X
authors.lastname: Wang
authors.forename: Juan
authors.initials: J
authors.lastname: Luo
authors.forename: Xiao-Yan
authors.initials: XY
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; C554019:MIRN130 microRNA, human; D035683:MicroRNAs; D002945:Cisplatin